On Thursday, Wedbush initiated protection on Zenas BioPharma, Inc. ZBIO, a clinical-stage international biopharmaceutical firm targeted on growing therapies for autoimmune illness.
Zenas BioPharma began buying and selling on the NASDAQ in September 2024. The corporate closed an upsized preliminary public providing of 15.22 million shares at $17 per share, elevating roughly $258.7 million in gross proceeds.
The corporate’s lead program obexelimab concluded enrollment within the Section 3 INDIGO trial for immunoglobulin-G4-Associated Illness (IgG4-RD). Topline information is predicted by the top of 2025.
The corporate additionally initiated the Section 2 MoonStone trial for Relapsing A number of Sclerosis (MS) and the Section 2 SunStone trial for Systemic Lupus Erythematosus (SLE).
Additionally Learn: PTC Therapeutics Reveals New Sepiapterin Information From Section 3 Research In Sufferers With Inherited Dysfunction, FDA Determination Anticipated In July
12-week major endpoint outcomes from the MoonStone trial are anticipated within the third quarter of 2025, and topline information from the SunStone trial are anticipated within the first half of 2026.
Analyst Martin Fan writes that obexelimab is a CD19 mAb that suppresses B cells, quite than eliminating them, to keep up immune safety towards infections.
Wedbush initiated protection with an outperform score and a value forecast of $35.
Analyst Fan writes that the distinctive security characteristic is very vital for situations like IgG4-RD, MS, and SLE, the place long-term security and immune safety affect remedy choices.
Demonstrating effectiveness in IgG4-RD and SLE reduces threat for ongoing applications and opens the door for enlargement into different illnesses the place B cell depletion is a longtime remedy technique.
“We encourage buyers to research differentiating options and market alternative for obexelimab forward of an upcoming potential FDA approval of depleting CD19 mAb, Amgen Inc’s AMGN Uplizna in IgG4-RD, set for April 3.”
“We maintain a long-term favorable view of ZBIO given its low-risk method focusing on a validated mechanism in irritation and immunology (I&I), with potential to develop biologics market uptake via its first-in-class method to sustaining protecting immunity,” Wedbush analyst writes.
Value Motion: ZBIO inventory is up 2.36% at $8.45 on the final examine Thursday.
Learn Subsequent:
Momentum–
Progress–
High quality–
Worth31.08
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
